Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | LIPE | Q05469 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.38 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL463692 | 0.83 | ESR1 (0.52) | KMT2ASMN1; SMN2HPGDCYP1A2CYP2D6 | |
| SCHEMBL406856 | 0.81 | MAPK1 (0.55) | KMT2ASMN1; SMN2HPGDKDM4ELIPE | |
| SCHEMBL14755860 | 0.81 | MAPK1 (0.46) | KMT2ASMN1; SMN2HPGDCYP1A2ALDH1A1 | |
| SCHEMBL12414036 | 0.81 | ALDH1A1 (0.43) | KMT2ASMN1; SMN2HPGDALDH1A1LMNA | |
| SCHEMBL17903050 | 0.78 | KMT2A (0.54) | KMT2ASMN1; SMN2HPGDKDM4EALDH1A1 | |
| SCHEMBL13541624 | 0.77 | ALDH1A1 (0.42) | KMT2ASMN1; SMN2HPGDCYP1A2CYP2D6 | |
| SCHEMBL12680145 | 0.76 | ALOX12 (0.43) | KMT2ASMN1; SMN2HPGDKDM4EALDH1A1 | |
| SCHEMBL16203508 | 0.76 | KMT2A (0.61) | KMT2ASMN1; SMN2HPGDCYP1A2CYP2D6 | |
| SCHEMBL13348627 | 0.76 | KDM4E (0.66) | SMN1; SMN2KDM4ECYP1A2CYP2D6PDE4A | |
| SCHEMBL12417213 | 0.76 | GLA (0.40) | KMT2ASMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012035346-A1 | PRODRUGS OF GUANFACINE | SHIRE, LLC (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20120065152-A1 | PRODRUGS OF GUANFACINE | SHIRE LLC (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065152-A1 | PRODRUGS OF GUANFACINE | UGT1A6, GDA, UGT1A3 | KMT2A 1095/4885SMN1; SMN2 1309/4885HPGD 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.